Johnson & Johnson (JNJ) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the fiscal third quarter ended September 29, 2024. Johnson & Johnson operates as a large accelerated filer with two primary business segments: Innovative Medicine and MedTech. The Consumer Health business (Kenvue) was separated in 2023 and is reported as discontinued operations. The company continues to navigate significant litigation regarding talc products and opioids while executing strategic acquisitions in oncology and cardiovascular technologies.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Sales to Customers | $22.47 Billion | $21.35 Billion | $66.30 Billion | $63.76 Billion |
| Net Earnings (Continuing Ops) | $2.69 Billion | $4.31 Billion | $10.64 Billion | $9.19 Billion |
| Diluted EPS (Continuing Ops) | $1.11 | $1.69 | $4.38 | $3.53 |
| Gross Margin | 69.0% | 69.1% | 69.3% | 69.0% |
| Operating Cash Flow (9M) | $17.28 Billion | $14.93 Billion | - | - |
| Total Debt | $35.75 Billion | $29.33 Billion | - | - |
| Cash & Equivalents | $19.98 Billion | $21.86 Billion | - | - |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales increased 5.2% in Q3 and 4.0% for the nine months ended September 29, 2024. Operational growth was 6.3% in Q3 and 5.6% for the nine months, partially offset by negative currency impacts of 1.1% and 1.6%, respectively.
- Earnings Decline: Net earnings from continuing operations decreased significantly in Q3 2024 compared to Q3 2023. This was primarily driven by a $2.0 billion charge for talc matters recorded in the third quarter and a $1.25 billion expense to secure global rights to the NM26 bispecific antibody (Yellow Jersey acquisition).
- Segment Performance:
- Innovative Medicine: Sales grew 4.9% in Q3. Oncology sales surged 18.7% driven by DARZALEX, ERLEADA, and CARVYKTI. Immunology sales declined 4.7% due to biosimilar competition for STELARA and REMICADE.
- MedTech: Sales grew 5.8% in Q3, boosted by the acquisition of Shockwave Medical (closed May 2024). Cardiovascular sales increased 26.2%.
- Acquisitions: The company completed the acquisition of Shockwave Medical ($13.1B enterprise value) and Yellow Jersey ($1.25B). Subsequent to the quarter, the acquisition of V-Wave Ltd was announced.
Guidance, Outlook, and Risks
- Talc Litigation: The company recorded a cumulative incremental charge of approximately $5.0 billion through Q3 2024 related to talc matters. The total present value of the reserve is approximately $12.0 billion. A "prepackaged" Chapter 11 bankruptcy plan for a subsidiary (Red River) was filed in September 2024 to resolve these claims, with a proposed resolution value of approximately $8.0 billion nominal ($6.475 billion present value), recently amended to increase the resolution by $1.75 billion.
- Opioid Litigation: The company has settled most government claims but continues to defend private litigant cases. Approximately 70% of the $5.0 billion opioid settlement has been paid.
- Patent Expirations: The company faces biosimilar competition for STELARA (launched in Europe, expected in US Jan 2025) and REMICADE. XARELTO sales declined due to share loss and unfavorable patient mix.
- Capital Allocation: The company repurchased $2.15 billion of common stock in the first nine months of 2024 and paid $8.84 billion in dividends. Net debt increased to $15.5 billion from $6.4 billion in the prior year, largely due to funding the Shockwave acquisition.
Investor Verification Checklist
- Talc Reserve Adequacy: Verify the sufficiency of the $12.0 billion reserve against the evolving bankruptcy proceedings and potential for additional claims outside the proposed plan.
- Stelara Biosimilar Impact: Monitor the timing and market share erosion of STELARA sales following the anticipated US biosimilar launch in January 2025.
- Acquisition Integration: Assess the integration progress and revenue contribution of Shockwave Medical and the development timeline for the Yellow Jersey (NM26) asset.
- Effective Tax Rate: Review the impact of the EU Pillar Two Directive and ongoing tax audits on the effective tax rate, which rose to 16.9% for the nine months ended September 2024.
- Debt Servicing: Evaluate the company's ability to service increased debt levels ($35.8 billion) while maintaining dividend payments and share repurchases.